SWAMI IYER, MD Houston, USA • Associate Professor, Leader, early drug development in Oncology, the Methodist Cancer Center • Dr Iyer is the Leader for Early Drug Development Program in Hematology and Oncology at the Methodist Cancer Center, Houston, Texas. He recently served as the Director of Hematological Malignancies at CTRC, and as an Assistant Professor of Medicine at the University of Texas Health Science Center (UTHSCSA). He is a physician scientist with laboratory interests in Heat shock proteins and has extensive expertise in clinical studies.
54
Embed
Ideal induction regimen for AML in adolescents and young adults
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
SWAMI IYER, MDHouston, USA
• Associate Professor, Leader, early drug development in Oncology, the Methodist Cancer Center
• Dr Iyer is the Leader for Early Drug Development Program in Hematology and Oncology at the Methodist Cancer Center, Houston, Texas. He recently served as the Director of Hematological Malignancies at CTRC, and as an Assistant Professor of Medicine at the University of Texas Health Science Center (UTHSCSA). He is a physician scientist with laboratory interests in Heat shock proteins and has extensive expertise in clinical studies.
Considerations for AML treatment in AYA.
Swami Padmanabhan Iyer, MD
Associate Professor, Weill Cornell Medical College
Houston Methodist Cancer Center
NCI Definition- adolescent and young adult (AYA) are cancer patients between the ages of 15 to 29 years old when they first had a diagnosis of cancer)
Considerations for Treatment in young patients with AML
• Overcome kinetics of AML- dose escalation of chemotherapy,
• Addition of a third chemotherapeutic agent• Are all younger age groups the same?• Understanding the biology-TCGA• Find the right targeted partners• Consolidation Intensification• Bone Marrow Transplantation
• 27 years old with WBC-34.6, Hgb-8.5 and platelets-20K.
• Trilineage dysplasia, t(6,9) and Flt-3 ITD positive.
• 80% of acute leukemia in adults• Median age of AML = 64 years- Public health• Incidence in USA rises by age group• Most common cause of cancer death in young
*Rates are per 100,000 and are age-adjusted.
Age-Specific Incidence Rates for AML
Survival in Adult AML by Time Period
Kantarjian H, et al. Cancer. 2010;116:4896-4901.
Overall
< 60 yrs
≥ 60 yrs
1.0
0.8
0.6
0.4
0.2
00 1 2 3 4 5 6 7 8
Yrs
Su
rviv
al P
rob
abil
ity
Era1960s1970s1980s1990s2000s
Total104530652
1007909
Died103492586849560
P < .001
1.0
0.8
0.6
0.4
0.2
00 1 2 3 4 5 6 7 8
Yrs
Su
rviv
al P
rob
abil
ity
Era1960s1970s1980s1990s2000s
Total104530652
1007909
Died103492586849560
P < .001
1.0
0.8
0.6
0.4
0.2
00 1 2 3 4 5 6 7 8
Yrs
Su
rviv
al P
rob
abil
ity Era
1960s1970s1980s1990s2000s
Total39
166263495486
Died39
164259461350
P < .001
Survival in AML by Age group
Considerations for Treatment in Adolescent Young Adults with AML
• Overcome kinetics of AML- dose escalation of chemotherapy, third agent, intensification
• Find the right targeted partner• Intensification and Consolidation• Bone Marrow Transplantation
Remission Induction in the young driven by the biology-
activating mutations
Cure
Clinically Detectable Disease
Induction Relapse Relapse
TimeTota
l Le
uke
mic
Cell
Num
ber
Questions to consider
• What is the ideal induction therapy?• What is the best anthracycline?• What is the best dose of cytarabine?• What is the ideal third agent?• Are all younger age groups the
same?• What are the targeted agents?• What is the best consolidation?
Considerations for Treatment in young patients with AML
• Overcome kinetics of AML- dose escalation of chemotherapy,
• Addition of a third chemotherapeutic agent• Are all younger age groups the same?• Understanding the biology-TCGA• Find the right targeted partners• Consolidation Intensification• Bone Marrow Transplantation
Considerations for Treatment in young patients with AML
• Overcome kinetics of AML- dose escalation of chemotherapy,
• Addition of a third chemotherapeutic agent• Are all younger age groups the same?• Find the right targeted partner- Sorafanib
and Gemtuzumabd• Consolidation• Bone Marrow Transplantation
Recent Randomized Trials of Dose-Intensification In AML
1. Fernandez HF, et al. N Engl J Med. 2009;361:1249-1259. 2. Lowenberg B, et al. N Eng J Med. 2009;361:1235-1248. 3. Pautas C, et al. J Clin Oncol. 2010;28:808-814. 4. Burnett AK, et al. ASH 2009. Abstract 484. 5. Lowenberg B, et al. N Engl J Med. 2011;364:1027-1036.
Trial Agent Results
ECOG E1900[1] Daunorubicin 90 mg/m2/day x 3 45 mg/m2/day x 3
Superior OS,CR with higher dose in pts < 60 yrs No benefit with higher dose if age ≥ 50 yrs,
adverse cytogenetics, or FLT3-ITD mutation
HOVON[2] Daunorubicin 90 mg/m2/day x 3 45 mg/m2/day x 3
No significant difference in pts ≥ 60 yrs Superior OS, CR, EFS with high dose in patients
60-65 yrs
ALFA-9801[3] Idarubicin 12 mg/m2/day x 4 or x 3Daunorubicin 80 mg/m2/day x 3
Superior CR with idarubicin x 3 or x 4 vs daunorubicin
No significant differences in EFS, OS, or relapse incidence
MRC AML15[4] FLAG-IdaDAADE
More durable CR with FLAG-Ida than with ADE or DA, but higher initial toxicity; no survival benefit
Remission, relapse, survival identical with high- vs intermediate-dose cytarabine for remission induction
Is intermediate dose superior to “standard” dose?
Holoweicki et al, J Clin Onc April 2012
Cladribine better than Fludarabine as third agent
A survival advantage of the DAC arm vs. DA arm was observed among:• age 50 years or
older (P = .005), • leukocyte count >
50 × 109/L (P = .03), and
• unfavorable karyotype (P = .03).
Pediatric vs.Adult Protocol
Treatment approaches in “standard arm” in Phase III US studies
AYA differences between ALL and AML procols
Considerations for Treatment in young patients with AML
• Overcome kinetics of AML- dose escalation of chemotherapy,
• Addition of a third chemotherapeutic agent• Are all younger age groups the same?• Understanding the biology-TCGA• Find the right targeted partner- Sorefanib
and Gemtuzumab• Consolidation• Bone Marrow Transplantation
Considerations for Treatment in young patients with AML
• Overcome kinetics of AML- dose escalation of chemotherapy,
• Addition of a third chemotherapeutic agent• Are all younger age groups the same?• Find the right targeted partner• Consolidation• Bone Marrow Transplantation
Creutzig, et al. Cancer. 2007 562-571
Age Groups in AML- <30 years studies-AML BFM 93/98, AMLCG 92/99 AML
HD93/98
Creutzig, et al. Cancer. 2007 562-571
Age Groups in AML- <30 years studies-AML BFM 93/98, AMLCG 92/99 AML
HD93/98
Creutzig, et al. Cancer. 2007 562-571
Age Groups in AML- <30 years-EFS by age group and cytogenetics
Tanner JA, et al. JCO suppl. 2009, Abstract#9506
MRC 10 study
AYA treated on Adult vs. Pediatric protocols comparison
Woods et al. ASH 2001, Abstract#462
CCG2891 Intensive vs.Standard Timing
Woods et al.Blood, 1996, 4979-4989
CCG2891 Intensive vs.Standard Timing
Woods et al.Blood, 1996, 4979-4989
CCG2891 Intensive vs.Standard Timing
Woods et al.Blood, 1996, 4979-4989
AYA treated on Adult vs. Pediatric protocols- Conclusions
Is survival lagging behind?
Considerations for Treatment in young patients with AML
• Overcome kinetics of AML- dose escalation of chemotherapy,
• Addition of a third chemotherapeutic agent• Are all younger age groups the same?• Understanding the biology-TCGA• Find the right targeted partner- Sorefanib
and Gemtuzumab• Consolidation• Bone Marrow Transplantation
Cytogenetics by Age group –Normal, CBF and 11q23
Grimwade. et al. Blood 1998,92-2322
MRC AML 10 clinical trial
TCGA Characterization of the- “Blackbox”- Mutations in AML.
The Cancer Genome Atlas Research Network. N Engl J Med 2013;368:2059-2074.
• First recognized somatic mutations-Transcription factors
• DNMT3, NPM1, CEBPA, IDH1/2 and RUNX1 mutually exclusive.
• Also for mutations in certain biologic classes- cohesins, splicesosome, signaling proteins and histone modifying proteins.
• TP53 worst outcome
Molecular risk-based therapies for AML with normal karyotype are based on new
markers
• Favorable mutations– NPM1: nucleophosmin member 1 gene– CEBPA: CCAAT/enhancer binding protein alpha– DNMT3
• Unfavorable mutations– FLT3-ITD: internal tandem duplication of the fms-related
tyrosine kinase 3 (FLT3) gene– MLL-PTD: partial tandem duplication of mixed-lineage
leukemia gene– BAALC: brain and acute leukemia gene, cytoplasmic– ERG: v-ets erythroblastosis virus E26 oncogene like (avian)– WT1– TP53
ASH Education Book 2006: Mrosek and Bloomfield
Prevalance of Mutations by age
Grimwade. et al. Blood 1998,92-2322
Hollink. et al. Leukemia, 2009;23-262-270, Schnittger et.al Blood 2005, 106
NPM1
Frohling et al, Blood, 2002, Meschinchi et.al Blood, 2006
Age prevalence of FLT3 ITD
Overall survival for FLT-3 in AYA
Frohling et al, Blood, 2002, Meschinchi et.al Blood, 2006
CBF AML with and without c-kit
Pollard et al, Blood 2010 and Paschka et al, JCO 2006